| A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma (NCT04845139) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-07-02 |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma (NCT05351593) | James Rubenstein | 2022-06-08 |
| Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL) (NCT05549284) | Affiliated Hospital to Academy of Military Medical Sciences | 2022-06-01 |
| Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma (NCT05347641) | The First Affiliated Hospital with Nanjing Medical University | 2022-06-01 |
| Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL (NCT05390749) | Peking Union Medical College Hospital | 2022-04-11 |
| First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) (NCT06454266) | Ningbo No. 1 Hospital | 2021-12-28 |
| Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma (NCT05334238) | Ruijin Hospital | 2021-12-01 |
| A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL (NCT05036577) | Huashan Hospital | 2021-10-10 |
| OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma (NCT04931368) | Klinikum Stuttgart | 2021-06-28 |
| Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL (NCT04906096) | Lakshmi Nayak, MD | 2021-06-01 |
| Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma (NCT04462328) | Washington University School of Medicine | 2021-04-29 |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma (NCT04831658) | Mingzhi Zhang | 2021-03-29 |
| Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma (NCT04899427) | Peking Union Medical College Hospital | 2021-03-24 |
| Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma (NCT04737889) | Henan Cancer Hospital | 2021-01-13 |
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) (NCT04457869) | Shandong New Time Pharmaceutical Co., LTD | 2020-11-01 |
| Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma (NCT04514393) | Huiqiang Huang | 2020-10-10 |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL (NCT04421560) | Dana-Farber Cancer Institute | 2020-08-01 |
| Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) (NCT04070040) | Beijing Sanbo Brain Hospital | 2020-02-13 |
| Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma (NCT04934579) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-01-01 |
| IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL (NCT04066920) | Deok-Hwan Yang | 2019-10-01 |
| Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma (NCT04083066) | Mingzhi Zhang | 2019-09-05 |
| R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty (NCT04120350) | Peking Union Medical College Hospital | 2019-08-16 |
| Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (NCT03495960) | International Extranodal Lymphoma Study Group (IELSG) | 2019-06-15 |
| BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT (NCT03733327) | Nanfang Hospital, Southern Medical University | 2018-11-01 |
| PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (NCT03120000) | PIQUR Therapeutics AG | 2017-12-01 |
| Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma (NCT02983942) | Beijing Tiantan Hospital | 2017-01-01 |
| Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years (NCT03582254) | Assistance Publique - Hôpitaux de Paris | 2016-06-13 |
| Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) (NCT02779101) | Prof. Dr. Matthias Preusser | 2016-06-01 |
| PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (NCT02669511) | PIQUR Therapeutics AG | 2015-11-12 |
| Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute (NCT02655744) | Chang Gung Memorial Hospital | 2015-11-01 |
| Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) (NCT02301364) | Memorial Sloan Kettering Cancer Center | 2014-11-20 |
| Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (NCT02203526) | National Cancer Institute (NCI) | 2014-08-14 |
| Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma (NCT02113007) | SCRI Development Innovations, LLC | 2014-07-01 |
| MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma (NCT02399189) | Jun Zhu | 2014-05-01 |
| Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (NCT01944943) | The Lymphoma Academic Research Organisation | 2013-02-01 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT01647971) | TG Therapeutics, Inc. | 2012-07-19 |
| Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma (NCT01421524) | Celgene | 2011-09-12 |
| Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL (NCT02836158) | Navy General Hospital, Beijing | 2010-09-01 |
| Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy (NCT02657785) | Navy General Hospital, Beijing | 2010-09-01 |
| Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma (NCT00712062) | University of Florida | 2009-02-01 |
| Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients (NCT00863460) | Institut Curie | 2008-10-03 |
| a Phase II Study in Primary Central Nervous System Lymphoma (NCT00455286) | National Health Research Institutes, Taiwan | 2006-11-01 |
| Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma (NCT00193973) | Trans Tasman Radiation Oncology Group | 2001-07-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |